CP.TO 0.88VRT 8.93NVDA -0.07TSM 5.21JPM 2.67ZST.TO 0.01HSAV.TO -0.1HSUV.U.TO 0.01
Merck & Company (MRK)

NYSE:MRK

Merck & Company (MRK)

143.93
-0.78 (0.54%)
as of Sep 11, 2026, 8:00:00 pm Market Open.
311 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
DON'T BUY

Merck & Company(MRK)

Jun 14, 2001
Patent expiries are a concern. Limited pipeline. Arthritis drug not moving well. Prefers Pfizer.
Photo of Noah Blackstein, B.A., CFANoah Blackstein, B.A., CFAUnlock Rating
$73.90

Stock price when the opinion was issued

$143.93

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
BUY

Merck & Company(MRK)

Jun 06, 2001
Likes both Pfizer and Merck in pharmaceuticals.
Photo of John Sinkins, CFAJohn Sinkins, CFAUnlock Rating
$73.95

Stock price when the opinion was issued

$143.93

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
BUY

Merck & Company(MRK)

Jun 05, 2001
Just came off a good technical support.
Photo of Ross HealyRoss HealyUnlock Rating
$75.33

Stock price when the opinion was issued

$143.93

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
BUY

Merck & Company(MRK)

May 17, 2001
Good, but has some patent expiries.
Photo of John McCollJohn McCollUnlock Rating
$78.60

Stock price when the opinion was issued

$143.93

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Merck & Company(MRK)

Apr 25, 2001
Not a fan at this time. Patent expiries coming up. Prefers Pfizer.
Photo of Noah Blackstein, B.A., CFANoah Blackstein, B.A., CFAUnlock Rating
$74.86

Stock price when the opinion was issued

$143.93

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Merck & Company(MRK)

Mar 12, 2001
Outlook for health care is good. Maybe a little expensive but a good long term hold.
Photo of Steven WipperstegSteven WipperstegUnlock Rating
$74.15

Stock price when the opinion was issued

$143.93

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
BUY

Merck & Company(MRK)

Jan 30, 2001
Have been selling at $90. Prefers Pfizer
Photo of Brendan CaldwellBrendan CaldwellUnlock Rating
$81.00

Stock price when the opinion was issued

$143.93

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
SELL

Merck & Company(MRK)

Jan 08, 2001
Drugs now coming off patents so future may be weaker
Photo of Noah Blackstein, B.A., CFANoah Blackstein, B.A., CFAUnlock Rating
$83.50

Stock price when the opinion was issued

$143.93

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
BUY

Merck & Company(MRK)

Dec 04, 2000
Expect Bush as president will be positive for US drug sector
Photo of Steven WipperstegSteven WipperstegUnlock Rating
$91.94

Stock price when the opinion was issued

$143.93

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
BUY

Merck & Company(MRK)

Oct 30, 2000
lower valuation and better growth than AMD
Photo of Noah Blackstein, B.A., CFANoah Blackstein, B.A., CFAUnlock Rating
$89.00

Stock price when the opinion was issued

$143.93

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
Showing 301 to 310 of 310 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

KMB -0.33$98.15
XLV -0.3$165.36
META 3.65$648.03
DAL 1.67$79.91
ORCL -2.66$150.28

Today's Top Picks

CP.TO 0.88$123.84
VRT 8.93$257.06
NVDA -0.07$218.29
TSM 5.21$433.24
JPM 2.67$356.23

Popular Articles

Latest Sell Signals

ORCL -2.66$150.28
ORCL -2.66$150.28
URI 0.04$989.12
BBD.B.TO -4.9$300.82
BN.TO 0.29$52.93

Most Recent Experts

Jenny Harrington, CEO, Gilman Hill Asset Management

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Shannon Saccocia, CIO, Boston Private

Shannon Saccocia, CIO, Boston Private

Boston Private

Kevin Simpson

Kevin Simpson

Capital Wealth Planning

Greg Newman

Greg Newman

Scotia Wealth Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

You may also like